14Jul
Japan Tightens Foreign Direct Investment Regulations on Life Science Companies - Prior notification requirements under the Japanese regulations were expanded to cover investments in life science companies.
On June 15, 2020, the Japanese government implemented new regulations that designate the manufacture of pharmaceuticals for infectious diseases and the manufacture of highly-controlled medical devices (medical devices that are classified as Class III or Class IV in Japan, such as a heart–lung machines and ventilators) as both "Designated Businesses" and "Core Businesses" under the Foreign Exchange and Foreign Trade Act of Japan ("FEFTA"). The new regulations were adopted in light of the COVID-19...
By:
Jones Day
Related
Navajo Transitional Energy Company, a wholly owned limited liability company of the Navajo Nation, i...
Read More >
When there is a post-merger dispute between the representative of the selling stockholders and the b...
Read More >
The long-awaited revision of the Form I-9 was released by the U.S. Citizenship and Immigration Servi...
Read More >
The North Carolina Industrial Commission announced several rule changes. The most impactful change i...
Read More >
If you’re seeking a special permit for a project, be prepared to prove that your proposal complies ...
Read More >
A new California law, Senate Bill 142 (“SB 142”), effective January 1, 2020, expands on existing L...
Read More >